Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 PharmaphorumNxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.NeuroscienceRead full story pharminent August 26, 2026 (Last updated: September 1, 2026) Pharmaphorum Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer’s cognition. Neuroscience Read full story Post navigation Previous: Jazz secures FDA approval for Ziihera in advanced HER2+ GEANext: Metsera backers establish new biotech armed with China-licensed immunology asset Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026